secwatch.observer — SEC 8-K summary
======================================

Issuer:     Zai Lab Ltd (ZLAB)
CIK:        0001704292
Form:       8-K
Filed at:   2024-05-08T23:59:59+00:00
Accession:  0001628280-24-021674
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Zai Lab Q1 product revenue $87.1M (+39% YoY); net loss $53.5M, VYVGART sales $13.2M
--------------------------------------------------------------------------------

- Product revenue $87.1M (+39% YoY; +43% at CER); ZEJULA $45.5M (+7%), VYVGART $13.2M (launch Sep 2023).
- Net loss $53.5M ($0.55 loss per ADS) vs $49.1M in Q1 2023; R&D $54.6M, SG&A $69.2M.
- Cash $750.8M at Mar 31, 2024, down from $806.5M at Dec 31, 2023.
- Appointed Andrew Zhu as Chief Commercial Officer for Greater China in April 2024.
- Regulatory milestones: sBLA submitted for efgartigimod SC in CIDP; potential NMPA approvals for repotrectinib, sulbactam-durlobactam, efgartigimod SC in gMG in 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1704292/000162828024021674/0001628280-24-021674-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1704292/000162828024021674/zlab-20240508.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-021674

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer